Replies to post #163037 on Biotech Values

[DewDiligence]

Gliknik collaboration with PFE could compete with MNTA’s sialylated-IVIG program:

http://www.gliknik.com/news/press-release-093013.pdf

BALTIMORE, MARYLAND, September 30, 2013 – Gliknik Inc., a privately held biopharmaceutical company, today announced that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. for GL-2045, Gliknik’s recombinant stradomer, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising results in a broad range of preclinical tests and is being developed as a potential treatment for a wide variety of autoimmune diseases, including those in which IVIG is clinically used.

…Under the terms of the license agreement, Pfizer will receive an exclusive worldwide license to GL-2045 for all therapeutic indications. Gliknik will receive an upfront payment of $25 million and is eligible to receive development, regulatory and commercial milestone payments. Gliknik is also eligible to receive tiered, double-digit royalties on net sales of any products that are commercialized pursuant to this license agreement.

…GL-2045 is Gliknik’s lead preclinical recombinant stradomer for autoimmune diseases. It has demonstrated potent efficacy in numerous preclinical tests and is in IND-enabling manufacturing. GL-2045 acts by presenting highly ordered multimers of normal human IgG Fc to its receptors.

MNTA’s sialylated-IVIG program is investigating the feasibility of producing the Fc portion of IVIG recombinantly (#msg-89344512, #msg-69595597).